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Abstract: Timely newborn screening and genetic profiling are crucial in early recognition and treatment 
of inborn errors of metabolism (IEMs). A proposed nosology of IEMs has inserted 1,015 well-characterized 
IEMs causing alterations in specific metabolic pathways. With the increasing expansion of metabolomics 
in clinical biochemistry and laboratory medicine communities, several research groups have focused their 
interest the analysis of metabolites and their interconnections in IEMs. Metabolomics has the potential to 
extend metabolic information, thus allowing to achieve an accurate diagnosis for the individual patient and 
to discover novel IEMs. Structural and functional information on 247 metabolites associated with 147 IEMs 
and 202 metabolic pathways involved in various IEMs have been reported in the human metabolome data 
base (HMDB). For each metabolic gene, a new computational approach can be developed for predicting a 
set of metabolites, whose concentration is predicted to change after gene knockout in urine, blood and other 
biological fluids. Both targeted and untargeted mass spectrometry (MS)-based metabolomic approaches 
have been used to expand the range of disease-associate metabolites. The quantitative targeted approach, in 
conjunction with chemometrics, can be considered a basic tool for validating known diagnostic biomarkers 
in various metabolic disorders. The untargeted approach broadens the identification of new biomarkers 
in known IEMs and allows pathways analysis. Urine is an ideal biological fluid for metabolomics in 
neonatology; however, lack of standardization of preanalytical phase may generate potential interferences in 
metabolomic studies. The integration of genomic and metabolomic data represents the current challenge for 
improving diagnosis and prognostication of IEMs. The goals consist in identifying both metabolically active 
loci and genes relevant to a disease phenotype, which means deriving disease-specific biological insights.
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Introduction
The term ‘inborn errors of metabolism’ (IEMs) was firstly 
coined in 1908 by Sir Archibald E. Garrod, a British 
physician, who observed patients with four genetically 
determined diseases: alkaptonuria, albinism, cystinuria, 
and pentosuria (1). He postulated that this cohort of 
a lifelong duration inherited conditions was caused by 
diminished activity or complete lack of a given enzyme 
which may either induce defects or block specific metabolic 
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pathways. Notably, Garrod launched the very novel notion 
of ‘chemical individuality’, thus providing the background 
for a pioneering vision of system biology (2). His peculiar 
view translated human chemical individuality in a setting 
of heredity and dynamic metabolism, that currently means 
interplay between genetics, epigenetics, proteomics and 
metabolomics. Garrod hypothesized that each single 
enzyme is controlled by a single gene; curiously, the notion 
that enzymes are protein was unknown among scientists at 
that time. The relevance of Garrod’s ideas was underrated 
for many decades. First, the practice of medicine in Garrod’s 
lifetime could not considerably benefit from discovery of 
congenital and inheritance nature of these diseases. Then, 
the apparent rarity of IEMs promoted medical profession 
to consider them as “clinically irrelevant”. Nowadays, based 
on the definition of rare disease (3), the estimated prevalence 
of IEMs is individually rare; however, the overall IEMs 
prevalence corresponds to about 1 of every 1,000 people (4). 
Geneticists also had a limited awareness on Mendelian’s 
principles, as well as on the physical nature of Mendel’s 
factors, namely genes. Probably, the most important 
obstacle for pervasive diffusion of Garrod’s theory was 
the dominant influence of Biometricians, who were 
conducting a battle against Mendelians (5). In the second 
edition of Inborn Errors of Metabolism, published by Garrod 
in 1923, he reported two further inborn errors: congenital 
porphyrinuria and congenital steatorrhea (6). From that time 
on, hundreds of IEMs have been discovered and continue 
to be discovered. Currently, 1015 well-characterized 
IEMs, causing alterations in specific metabolic pathways, 
have been described in the literature (7); additional 111 
supposed less well-characterized conditions that might be 
classified as IEMs do not meet strict criteria for inclusion 
in the current nosology (7). IEMs represent around 80% 
of rare (orphan) diseases, although their prevalence is 
highly variable, ranging from 25:100,000 for congenital 
hypothyroidism to 0.4:100,000 for disorders like branched 
chain ketoaciduria. Most IEMs consist of enzymes and 
transport proteins defects, leading to either inadequate 
production of critical substances (high-energy metabolite 
intermediates, hormones, proteins, lipids, metabolites, 
and so on) or undue accumulation of toxic metabolites. 
Due to their considerable heterogeneity, IEMs can be 
categorized by several criteria. Indeed, various informal 
systems of classification are available in the literature, based 
on clinical features, pathophysiology, affected enzymes, 
affected organelle and many other criteria. Nevertheless, 
no unique, universal classification system still exists. The 
Society for the Study of Inborn Errors of Metabolism 
(SSIEMs) has grouped IEMs according to the principle of 
homogeneity. Each group consists of diseases belonging 
to the same biochemical pathway, detected by the same 
diagnostic method, and treated by equivalent emergency 
protocol standards as well as by similar long-term 
management (8). A recent classification divides IEMS into 
two large clinical categories: (I) IEMs either involving only 
one functional system, or affecting only one organ; (II) IEMs 
characterized by biochemical impairments either affecting 
one metabolic pathway common to a large number of cells/
organs, or restricted to one organ but giving rise to systemic 
disorders (9). The latter has been further categorized 
into three groups: disorders of intermediary metabolism 
affecting small molecules, disorders involving primarily 
energy metabolism, and disorders involving complex 
molecules (Table 1).
Laboratory screening of IEMs 
In most developed nations, and in several low-income 
countries, each newborn is screened for IEMs by dry 
blood spot (DBS) testing. Timely newborn screening 
and genetic profiling are crucial in early recognition and 
treatment of IEMs. Diagnostic delay may result in acute 
metabolic decompensation, progressive neurologic injury, 
or death. The laboratory approach for screening IEMs 
can be schematically represented by four steps: (I) general 
metabolic screening test; (II) specific metabolite assays; 
(III) enzymes studies; (IV) DNA analysis. From their 
introduction in public health care, newborn screening 
programs have been expanded to include now more than 50 
inherited metabolic disorders, including aminoacidopathies, 
organic acidemias, fatty acid oxidation disorders, and 
lysosomal storage disorders. The definitive diagnosis is 
based on more specialized tests such as plasma amino acid 
profiling, urine organic acid profiling, plasma acylcarnitine 
profiling, free fatty acid profiling, pyruvate, acetoacetate, 
3-hydroxybutyrate, mucopolysaccharides, oligosaccharides, 
enzyme activity assays, functional assays, and mutational 
analyses. In 1980s, tandem mass spectrometry (MS/MS) 
was introduced as a reference technique for newborn 
screening, because of its capacity of screening a wide range 
of previously unscreened IEMs by a single test performed 
on a DBS. Currently, MS/MS techniques are routinely used 
for neonatal screening of IEMs, since they are rapid, highly 
sensitive and specific, require very low sample volume 
and offer a high throughput. As a priority objective of a 
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Regional Genetics Collaborative project funded by the U.S. 
Health Resource and Service Administration (HRSA), in 
2004 a collaborative project was launched, called Region 
4 Stork (R4S). The main goals were facilitating universal 
implementation of newborn screening by MS/MS and 
confirmatory testing of newborns for IEMs, and improving 
laboratory quality of expanded newborn screening (10). 
The project was also aimed to reach three more objectives: 
(I) achieving uniformity of testing panels by MS/MS, 
thus maximizing detection rate of affected newborns; 
(II) improving cumulative analytical performance; and 
(III) achieving and maintaining the lowest achievable 
rates of false positive and false negative results (11). The 
catalyst of this project is a multivariate pattern recognition 
software [Collaborative Laboratory Integrated Reports 
(CLIR)], which can significantly improve post-analytical 
interpretation of complex metabolic profiles (12). This has 
led to identification of 114 biomarkers, to be used in the 
newborn screening (13). In 2012, the R4S database became 
part of the Newborn Screening Translational Research 
Network, an initiative funded by the National Institute of 
Child Health and Human Development (NICHD). 
Metabolomics, metabolites and metabolome
Metabolomics and metabolism share as their root the 
ancient Greek word “metabol“, which means “change”. The 
term metabolomics, defining the comprehensive analysis of 
small molecules involved in metabolic pathways of living 
organisms, was coined by Oliver Fiehn in 2002 (14). By 
using high throughput technologies, metabolomics allows 
identification and measurement of metabolites recognizable 
in a given biological sample. The term metabonomics 
was previously introduced to define the dynamic 
metabolic response of living systems to perturbations 
over time, mapped by appropriate analytical and statistical 
techniques (15). Nevertheless, a large degree of overlap 
in the way metabolomics and metabonomics have been 
used in the literature has led to their almost complete 
interchangeability, being analytical and modeling procedures 
identical (16). Metabolites refer to all the organic small 
molecules with a molecular weight <1,800–1,500 Dalton. 
These can act as substrates or products in biochemical 
metabolic pathways (17). Metabolites such as lipids, sugars, 
and amino acids are byproducts of cellular metabolism and 
control the way a cell transfers energy to, or communicates 
with, other cells. Indeed, metabolites show abrupt changes 
in their amount and composition within a biological system 
in response to either physiopathological perturbations 
or therapeutic treatments. Thus, they can generate vital 
information in patients care by unveiling alterations in 
biochemical pathways involved in diseases and/or in drug 
administration. Metabolomics can be considered one of the 
earliest medical and biological sciences. In ancient Greece, 
urine sweetness, an organoleptic feature due to excretion 
of metabolites into urine, was used to detect glycosuria in 
diabetes. Most of currently available clinical laboratory 
tests consist of measurement of blood and urine metabolites 
concentration (e.g., uric acid, glucose, creatinine, and so 
forth). However, this conventional approach is mainly 
hypothesis-driven and reductionist. Notably, it allows 
neither complete characterization of a biological system, nor 
Table 1 Classification of IEMs restricted to one organ but giving 
rise to systemic disorders [according to (9)]
Inborn errors of metabolism category 2:
Disorders of intermediary metabolism affecting small molecules
	 Amino acid catabolism
	 Most organic acidurias
	 Urea cycle defects
	 Galactose & fructose defects
	 Porphyrias
	 Metal disorders
	 Neurotransmitter synthesis
	 Brain amino acid synthesis
Disorders involving primarily energy metabolism
	 Deficiencies of glucose cerebral transporter
	 Deficiencies of glucose hepatointestinal transporter
	 Mitochondrial defects
	 Cytoplasmic energy defects
Disorders involving complex molecules
	 Lysosomal storage disorders
	 Peroxisomal disorders
	 Carbohydrate-deficient glycoprotein (CDG) syndrome
	 Purine and pyrimidine
	 Cholesterol and bile acid synthesis
	 Intra-cellular triglycerides, phospholipids, 
glycosphingolipids synthesis and remodelling
IEMs, inborn errors of metabolism.
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systemic analysis of complex functional interrelationships 
between metabolites. Conversely, metabolomics offers a 
‘top-down’ integrated view of biochemistry in complex 
organisms. This marks a basic difference between the 
current evaluation of single metabolites and the analysis of 
the whole set of metabolites recognizable in a biofluid, cell 
or tissue extract, namely the metabolic profile. The latter 
depicts an accurate view of the highly dynamic metabolic 
network, offering a plethora of biochemical data that 
can be analyzed and interpreted, and demonstrating the 
assumption that ‘the whole is more than the merely sum of 
parts’, as stated by Aristotle more than two thousand years 
ago (18). In 1998, Oliver et al. coined the word metabolome 
to define the holistic quantitative amount of metabolites in 
a given sample (19). Later, the definition has been adjusted 
as the molecular phenotype originating from the genotype’s 
interaction with the environment (20). The metabolome 
represents the molecular fingerprint of a biofluid or a tissue, 
and is highly dynamic. Changes in metabolites composition, 
concentration and interactions depend on complex interplay 
with different organs, environment and gut microbiota. 
Although the term environment embraces a wide spectrum 
of definitions, it can be argued that environment addresses 
all non-genetic factors influencing the homeostasis of 
reaction chains in metabolic pathways. 
Metabolome profiling methods
The human metabolome shows a very high degree of 
complexity, requiring specific and more complex analytical 
platforms, methods and data analysis compared with those 
used for other “-omics”. Indeed, genomics, transcriptomics 
and proteomics can profile large molecules made of 
chemical building blocks, namely nucleotides and amino 
acids, constituted by a simple and limited set of subunits 
(4 and 20 for nucleic acids and proteins, respectively). 
Thus, the order combination of nucleotides or amino 
acids is what matters for identification and functional 
analysis of DNA, RNAs and proteins. In other words, the 
complexity of DNA, RNAs and proteins, closely related 
with the corresponding biological information, is the order 
of subunits. Conversely, no sequencing approach can be 
used for the analysis of metabolites in a complex biofluid or 
tissue, because no obvious order exists. Metabolites should 
be individually and selectively differentiated, identified, 
and quantified across a wide quantitative and qualitative 
chemical space (21). In addition, metabolites either 
individually or clustered in groups, can differ from each 
other for physicochemical properties. This high variability 
adds another layer of complexity to metabolomics. Nuclear 
magnetic resonance (NMR) spectroscopy and MS are 
reference methods for extracting comprehensive and 
unbiased chemical information from complex mixtures 
of metabolites. NMR spectroscopy measures an intrinsic 
magnetic property of atomic nuclei, namely the spin (22). 
One dimensional proton NMR (1H NMR) spectroscopy 
is the most common NMR approach in metabolomics. 
NMR has several advantages (23), the most important is 
the absence of any preanalytical step, which means avoiding 
sample manipulation, potential destruction of metabolites 
structure and reduction of interferences due to the co-
migration of metabolites with compounds previously used 
for sample preparation. Further advantages consist of 
rapid analytical time, wide coverage of chemical classes, 
and high reproducibility. MS is very popular across 
metabolomic studies, being less expensive than NMR 
and highly sensitive for characterizing complex molecular 
phenotypes. Two main approaches are used in MS-based 
methods, (I) the direct infusion mode, consisting of the 
direct injection of biological samples into the ionization 
source of the mass spectrometer, and (II) MS in conjunction 
with high resolution separation techniques such as liquid 
chromatography (LC-MS), gas chromatography (GC-MS) 
and capillary electrophoresis (CE-MS). These preventive 
separation methods reduce the complexity of mass spectra, 
providing additional information about physicochemical 
properties of metabolites. The direct infusion mode has the 
advantage to be very helpful for quantifying metabolites in 
complex mixtures. Nevertheless, it can induce an extensive 
ion suppression, causing inability to separate isobaric 
and isomeric compounds (24). Currently, LC-MS is the 
most widely applied platform for targeted profiling of 
both polar and non-polar compounds, CE-MS is useful 
for analysis of polar charged metabolites, whilst GC-MS 
is helpful for analysis of volatile metabolites, as well as 
those made volatile by chemical derivatization (25). The 
introduction of ultra performance liquid chromatography 
(UPLC) and supercritical fluid chromatography (SFC) 
coupled with MS has improved both sample throughput 
and analytical sensitivity. In particular, the adoption of 
these techniques leads to a high-resolution separation of 
lipids, which constitute a large subset of metabolome and 
should be carefully analyzed in many IEMs. Due to large 
differences in abundance and huge diversity of chemical 
structures, there is a growing trend in metabolomics to 
perform tandem studies, in which the same sample is 
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analyzed by both NMR and MS (26). Indeed, no single 
available technology can definitively characterize the whole 
metabolome in a given biological sample (27).
Metabolomics for IEMs
With the increasing expansion of metabolomics in clinical 
biochemistry and laboratory medicine communities, 
several research groups have focused their interest on the 
application of metabolomics for diagnosing and monitoring 
of IEMs, pursuing a deepened analysis of metabolites and 
their interconnections. Despite its unquestionable clinical 
value and its primary role in public health care, newborn 
screening offers only a snapshot of a very small subset of 
metabolic alterations; moreover, a number of IEMs are not 
identifiable by routine newborn screening programs. On 
the other hand, the metabolic profiling could significantly 
contribute to extend metabolic information with two main 
goals: achieving an accurate diagnosis for the individual 
patient, and discovering novel IEMs (28-30). However, 
genetics and metabolomics are not mutually exclusive. 
For each metabolic gene a new computational approach 
can be developed for predicting a set of metabolites whose 
concentration is predicted to change after gene knockout 
in urine, blood and other biological fluids (31). Structural 
and functional information on 247 metabolites associated 
with 147 IEMs and 202 metabolic pathways involved in 
various IEMs are reported in the human metabolome data 
base (HMDB). This tool was launched in 2005 by a multi-
institutional, multi-national project (Human Metabolome 
Project) (32), and was designed to facilitate the investigation 
of links connecting genes, diseases and metabolites (33). 
HMDB is basic for elucidating the metabolic pathways 
disturbed, or blocked, in a given IEMs and, for facilitating 
discovery, identification and quantification of key 
metabolites in patients with IEMs. Over the last decade, 
a growing number of metabolomic studies focused on 
IEMs have been published, with a special interest for those 
diseases displaying marked phenotypic and genotypic 
variability among affected patients, and therefore hard to 
diagnose by newborn screening programs. A paradigmatic 
example  i s  Fabry  d i sease ,  an  X- l inked complex , 
multisystemic lysosomal storage disorder caused by a 
deficiency of the enzyme -galactosidase A and characterized 
by accumulation of globotriaosylsphingosine (lyso-Gb3) and 
globotriaosylceramide (Gb3) in biological fluids and tissues. 
By using an UPLC electrospray ionization time-of-flight 
(UPLC-ESI-TOF-MS)-based metabolomic approach, a 
Canadian researcher group aimed to find novel biomarkers 
reflecting disease severity and progression. In a sequence 
of consecutive studies, they found up to 15 different 
isoform/analogs of Gb3 (34-37) and 22 galabiosylceramide 
(Ga2) isoforms/analogs of Ga2 in urine of untreated Fabry 
patients (38). The discovery of these isoforms contributed 
to provide new insights into the pathophysiology of Fabry 
disease and into mechanisms inducing alterations in 
metabolic pathways.
Metabolomic studies can be conducted following two 
strategies, i.e., the targeted and the untargeted approach. 
In studies using the targeted approach, specific metabolites 
are detected, quantified and compared to establish reference 
ranges. The untargeted approach consists of analysis of all 
detectable metabolites known and unknown in a single test 
performed on a biological fluid or tissue, to determine any 
perturbation of single or multiple metabolites and of related 
biochemical pathways (40). Untargeted metabolomics can 
be considered a ‘discovery mode’ process. Both targeted 
and untargeted MS-based metabolomics approaches 
have been used to expand the range of disease-associate 
metabolites (41).
The targeted metabolomic approach
The quantitative targeted metabolomics in combination 
with chemometrics have been applied in several studies on 
IEMs for clinical validation of known diagnostic biomarkers. 
Aminoacidopathies, organic acidurias and fatty acid 
oxidation disorders were investigated by using the targeted 
metabolomic approach (30). A recent study evaluated an 
LC-MS/MS-based comprehensive targeted metabolic panel 
of 220 clinically relevant metabolites, encompassing a broad 
range of genetic metabolic disorders (41). The evaluation 
was made on animal tissue samples, on 20 healthy adults 
volunteers and on 56 DBS samples from patients with eight 
different IEMs. Results showed that the targeted panel 
is sensitive, robust and potentially useful as a screening 
tool for a large group of IEMs, thus avoiding multiple, 
time-consuming and expensive biochemical assays which 
would cause delay in clinical management. By analyzing 
163 plasma metabolites in 50 controls and 34 patients 
with defects in amino acid metabolism, organic acidurias 
and mitochondrial defects, this combination has led to 
detecting all patients with inherited metabolic disorders, 
with complete discrimination for each patient sample from 
control samples (42). A targeted metabolomics approach was 
used to test whether specific plasma sphingolipids are useful 
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as outcome measures in Niemann-Pick C1 (NPC1) disease 
therapies (43). As widely known, aberrant sphingolipid 
metabolism is the metabolic hallmark of NPC1 disease. 
By using a MS-based metabolomic profile, researchers 
identified a panel of plasma and cerebrospinal fluid (CSF) 
sphingolipids that were increased in human NPC1 subjects 
and, even more relevant, that responded to therapeutic 
treatment both in patients and in animal models.
The untargeted metabolomic approach
The untargeted approach is highly descriptive. A single 
metabolomic analysis provides a plethora of information 
currently requiring multiple targeted panel assays for 
organic acids, carnitine biosynthesis intermediates, 
acylcarnitines, nucleic acids, amino acids and other 
metabolites. The application of untargeted metabolomics 
to the diagnosis of metabolic diseases was early conducted 
for  charac ter i z ing  methy lmalonic  ac idemia  and 
propionic acidemia (44). The study demonstrated that 
the simultaneous profiling and detection of hundreds to 
thousands metabolites increases the likelihood of identifying 
new compounds associated with these diseases, such as five 
additional acyl-carnitine metabolites and -butyrobetaine. 
The study represents a cornerstone supporting the notion 
that untargeted approach enhances the identification of new 
biomarkers in known disorders (44). More recently, 120 
plasma samples from patients with a confirmed IEMs and 70 
from patients tested for IEMs but with normal results were 
analyzed by using an untargeted metabolomic workflow 
based on three separate MS platforms run in parallel (GC-
MS, LC-MS in positive ion mode and LC-MS in negative 
ion mode) (45). Based on pathway analysis, the authors 
successfully screened 20 of 21 IEMs, whilst homocysteine, 
methylmalonic acid, tetradecenoylcarnitine (C14:1), 
and guanidinoacetate (GAA) were not identified. This 
limitation was counterbalanced by identification of multiple 
metabolite perturbations associated with homocystinuria 
and methylmalonic acidemia, thus confirming the usefulness 
of untargeted approach for IEMs screening when patient’s 
phenotype is undifferentiated. An untargeted approach 
combining 1H NMR spectroscopy and LC-MS/MS allowed 
elucidating the metabolic abnormalities and pathogenesis 
of Barth syndrome, a rare X-linked disorder consisting of 
deficiency in tafazzin expression and leading to abnormal 
cardiolipin content and reduction of mature cardiolipin (46). 
All metabolites detected by MS displayed a clear separation 
between samples from patients with Barth syndrome and 
controls. Interestingly, the pathway enrichment analysis 
showed the association between broad, previously unknown, 
metabolic impairments with etiology of Barth syndrome, 
thus revealing new potential therapeutic targets. Untargeted 
metabolomics has been applied to investigate plasma 
metabolome in 12 patients with long-chain hydroxy-acyl-
CoA dehydrogenase and carnitine palmitoyltransferase 2 
deficiency as well as in 11 healthy controls (47). Overall, 832 
metabolites could be detected. When results were analyzed 
following the metabolic profile of complex lipids (model 2), 
partial least squares-discriminant analysis (PLS-DA) score 
plot revealed 117 non-acylcarnitine variables discriminating 
controls from individuals with mitochondrial fatty acid 
oxidation disorders. This analysis had the potential to 
recognize the risk and severity of disease, as well as the 
identification of fatty acid oxidation disease subtypes. 
Finally, the untargeted global metabolic phenotyping was 
successfully tested in the CSF of a pediatric cohort with 
various IEMs (48). More than 60% of metabolites detected 
in CSF were simultaneously present in blood and urine, 
thus suggesting that a single CSF sample processed with an 
integrated metabolomics workflow can be used to identify a 
large breadth of biochemicals useful for identifying altered 
metabolic pathways associated with IEMs. 
Metabolomics applied to the screening of IEMs
The potential role of metabolomics for IEMs screening was 
firstly explored on two inherited metabolic disorders, i.e., 
phenylketonuria and maple syrup urine disease (49). For 
the latter, characterized by increased levels of branched-
chain amino acids, no screening was available at that 
time. DBS were collected and analyzed by 1H NMR 
spectroscopy. Metabolomics clearly discriminated not 
only the metabolome of samples from healthy children 
from that of children with maple syrup urine disease, 
but also represented a specific metabolic screening for 
this disease, allowing to discriminate phenylketonuria 
from maple syrup urine disease (49). In a study enrolling 
six patients with six distinct IEMs (argininosuccinic 
aciduria, classic homocystinuria, classic methylmalonic 
acidemia, maple syrup urine disease, phenylketonuria and 
type II tyrosinemia) and six controls, urine metabolome 
was explored by combining desorption electrospray 
ionization mass spectrometry (DESI-MS) with 1H NMR 
spectroscopy (50). This combination clearly discriminated 
the urine metabolic profile of each patient from that of 
remaining patients and from that of controls, thus offering a 
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rapid and accurate screening of urine from diseased patients 
for a better characterization of IEMs. With the aim to 
reduce the false positive rate of traditional electrospray MS/
MS newborn screening, a group of researchers proposed to 
introduce a novel approach based on direct flow injection 
analysis, namely nanospray ionization in conjunction with 
high-resolution MS (HR MS) (51). The metabolic profile 
of DBS was mapped, resulting in selective detection of 
more than 400 individual metabolites, including complex 
lipids, bile acids, organic acids, fatty acids, carbohydrates, 
acylcarnitines. Importantly, this strategy had the ability 
to screen galactosemia by detecting hexose and hexose-
phosphate, as well as many other diseases involving global 
changes in metabolome. Expanded newborn screening 
for preclinical diagnosis of IEMs by using LC-MS/MS 
targeted metabolomics was included in a research project 
carried out in southern Italy, between 2007 and 2014 (52). 
The study was focused on identification of newborns at risk 
for fatal diseases, including fatty acid oxidation disorders, 
organic acidemia, branched chain amino acid deficiency, 
hyperammonemia, and maternal acquired metabolic 
disorders. Results supported the important added value 
of metabolomics for improving prediction of clinical 
risk by a presymptomatic diagnosis of IEMs. Recently, 
a quantitative/qualitative HR MS platform tailored to 
metabolic disease was developed and validated, with the 
aim of detecting and quantifying many classes of both polar 
and non-polar/hydrophobic metabolites (53). This platform 
covers a multitude of various metabolites, including those 
commonly quantified by combining separate analytical 
instruments. A multi-center 1H NMR spectroscopy-based 
clinical study aimed to assess analytical variability on 
20 metabolites always detectable in neonatal urine along 
with 45 pathological metabolites. Results from healthy 
newborns were embodied into a NMR database (54). The 
protocol involved 14 clinical centers, with collection of 
989 urine samples from newborns aged 24 to 168 hours 
after birth. Nearly all samples (89.5%) were measured 
twice in two different laboratories. Reference ranges were 
established for 20 metabolites. The spectra of healthy 
neonates were characterized; statistical outliers were 
identified, and the urine spectra of diseased newborns were 
acknowledged and stored.
Urine sample for metabolomics: benefits and 
pitfalls
Urine is an ideal biological fluid for metabolomics in 
neonatology; since is sterile, easy to obtain in large 
volumes and minimally invasive. More importantly, 
the characterization of urine metabolome significantly 
contributes to identify biochemical signatures of cellular 
metabolism involved in many IEMs (55). The high 
reliability of urine samples for metabolomics applied to 
diagnosis and monitoring of IEMs was demonstrated in 
a recent study, performed on a sample consisting of 18 
different IEMs, including 34 from subjects diagnosed with 
an IEM and 66 from those without a final diagnosis of 
IEM (56). Over 1,200 metabolites could be detected. 
Moreover, biochemical signatures for 16 IEMs were 
unequivocally identif ied,  while X-linked creatine 
transporter deficiency and ornithine transcarbamylase could 
not. However, the two patients with the two unidentified 
diseases were under therapeutic treatment, which may 
mask disease-specific biomarkers signature. The GC-MS-
based urine metabolic profile for IEMs newborn screening 
was investigated in a retrospective study on 23,140 urine 
samples in an Indian setting (57). The study showed that 
GC-MS metabolomic approach significantly improved 
the effectiveness of neonatal screening programs in that 
Country, whilst also appeared more comprehensive for 
screening metabolic defects, easier and non-invasive. 
Beyond primary lactic acidemia, organic acidemia, and 
aminoacidopathies, GC-MS-based metabolomics revealed 
alkaptonuria, canavan disease, and 4-hydroxybutyric 
aciduria. Although highly advantageous, urine analysis 
may be biased by lack of standardization of preanalytical 
phase. In particular, the method use for collecting sample 
and urea removal protocol for samples analyzed by GC-
MS are crucial steps. They may both generate potential 
interferences in metabolomic studies. Most methods for 
urine collection (e.g., midstream specimens, clean catch 
specimens, urine collection bags, suprapubic catheter) are 
infeasible in the neonatal age; one popular method for 
collecting urine from babies is disposable diapers. Once the 
production and sale of ultra-absorbent diapers commenced, 
it became impossible to collect urine samples directly from 
the diaper itself. To overcome this problem, a cotton ball 
or a cotton pad were inserted into the disposable diaper, 
and the so-called ‘diaper plus cotton ball’ was introduced 
into practice (58). In such way, urine can be absorbed by 
the cotton. Unfortunately, the ‘diaper plus cotton ball’ 
technique may be a source of sample contamination. An 
experimental study examined eight diaper brands, observing 
that each diaper brand had a unique contaminant profile 
or signature, which could potentially interfere with results 
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obtained both by NMR- and LC/MS-based metabolomics 
approaches (59). Authors recommended the metabolic 
characterization of the ‘diaper and cotton ball’ brand used 
in a given study prior to initiating the evaluation of urine 
metabolome. They also strongly discouraged the use of 
multiple diaper brands in a metabolomics study. Following 
this recommendation it is possible to evaluate whether 
or not contaminant profiles are minimal or manageable. 
Several additional factors should carefully be taken into 
account before analyzing results, since these factors could 
significantly influence extent and metabolic profile of a 
diaper contaminants, such as temperature, urine pH and 
osmolality, length of time that urine is exposed to diaper 
before collection, bacterial contamination and baby weight. 
Urine analyzed by GC-MS should be pre-treated by 
urease to remove the significant urea amount, since this 
metabolite may interfere with chemical derivatization, 
thus leading to incomplete chemical transformation. The 
lack of standardization of this step, namely unbalanced 
combination between volume of enzyme (urease) added 
to the sample with the sonication time, can lead to 
incomplete urea removal and thus to chromatographic 
column overloading, peak distortions, and likelihood of co-
eluting metabolites peaks. A very recent study established 
a standardized protocol for urea removal, obtaining the 
optimal combination between urease volume and sonication 
time (60).
Future perspectives
Although IEMs are disorders genetically transmitted, 
typically in an autosomal recessive or X-linked recessive 
fashion (e.g., Duchenne muscular dystrophy), the model 
‘one gene-one enzyme-one disease’ can no longer be 
considered appropriate. Indeed, the genome alone may turn 
out to be inadequate to explain the complexity of human 
metabolic diseases (61). On the other hand, metabolites 
derive from intermediate biological processes that bridge 
gene function, non-genetic factors, and phenotypic 
end points (62). Therefore, metabolic phenotypes can 
provide novel insights into gene function, biomarkers for 
diagnosis and prognostication, and mechanisms of disease 
pathogenesis. Metabolomics offers the opportunity to map 
metabolic pathways disturbances, as well as the network of 
metabolites involved in the origin of a metabolic disease 
(63,64). Actually, the best approach to metabolomic 
study of complex IEMs may be the combination between 
untargeted approach, which means to span the breadth of 
metabolome and perform pathways analysis, with targeted 
approach, which means measuring specific metabolites and 
assessing their reference intervals. This strategy, adopted 
in several studies (65-67), facilitates the identification 
of subtle phenotypes and biomarkers correlated with a 
specific phenotype. The integration of genomic with 
metabolomics data represents the current challenge for 
improving diagnosis and prognostication of IEMs. The 
goals here are identifying both metabolically active loci 
and genes relevant to a disease phenotype, thus deriving 
disease-specific biological insights (68). For example, the 
definitive diagnosis of maple syrup urine disease should be 
based at least on: (I) identification of pathogenic variants 
in either DBT [encoding dihydrolipoyl transacylase (E2) 
subunit], BCKDHB [encoding BCKA decarboxylase (E1) 
β-subunit] or BCKDHA [encoding BCKA decarboxylase 
(E1) α-subunit] genes; (II) measurement of high levels of 
alloisoleucine, isoleucine, leucine, valine; (III) detection of 
branched-chain 2-oxo acids (69). In the so-called pathway-
based approach, genes in enriched metabolic pathways 
harbor variants that elucidate the patient’s biochemical 
phenotype (70). In conclusion, MS-based metabolomics 
is currently used in many published studies on IEMs (71). 
Concomitantly, most clinical laboratories have included 
MS in their technical equipment over the past 5 years. 
Therefore, there is no barrier to introducing metabolomics 
into clinical practice for expanding newborn screening 
programs.
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